A premium-valued dermatology pure-play compounding growth through a blockbuster biologic (Nemluvio) and next-gen aesthetics (Relfydess/Sculptra), with tariffs, FDA timing, and consumer cyclicality as the key swing factors.
Overview
Galderma Group AG is presented as the world’s leading pure-play dermatology company with a comprehensive portfolio spanning everyday skincare to high-barrier medical therapeutics and premium aesthetics. Headquartered in Zug and listed on SIX in March 2024, the company’s core strategic pillar is its “Integrated Dermatology Strategy,” which links Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology to create cross-segment synergies and durable demand. In FY2025, Galderma delivered record net sales of $5.207B (up 17.7% at constant currency), surpassing the $5B milestone for the first time, driven mainly by strong volumes and favorable mix. Segmentally, Injectable Aesthetics reached $2.572B (+11.5% CC), Skincare $1.449B (+9.3% CC), and Therapeutic Dermatology $1.185B (+50.2% CC) led by Nemluvio. The financial model is characterized by premium economics (73.9% gross margin), early signs of operating leverage (Core EBITDA $1.211B), and rapid balance-sheet strengthening (net leverage down to ~1.5x Core EBITDA by end-2025). Commercially, Galderma’s deep HCP engagement—particularly through the GAIN training ecosystem—supports brand loyalty and adoption across products. The U.S. remains the largest market (43% of sales), with International markets at 57% and notable acceleration in China and India. With EQT fully exited and L’Oréal holding ~20%, the company is framed as entering a new phase of scaled growth with a long-term shareholder base and an ambition to cement leadership across global dermatology.